Status:
UNKNOWN
Stem Cell Educator Therapy in Diabetes
Lead Sponsor:
Throne Biotechnologies Inc.
Collaborating Sponsors:
Chinese PLA General Hospital
Conditions:
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20-60 years
Phase:
PHASE2
Brief Summary
Stem Cell Educator (SCE) therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent Cord Blood Stem Cells (CB-SCs) in vitro, and r...
Eligibility Criteria
Inclusion
- Patients are screened for enrollment in the study if both clinical signs and laboratory tests meet the diagnosis standards of American Diabetes Association.
Exclusion
- Exclusion criteria are any clinically significant diseases in liver, kidney, and heart. Additional exclusion criteria are no pregnancy, no immunosuppressive medication, no viral diseases or diseases associated with immunodeficiency.
Key Trial Info
Start Date :
November 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03390231
Start Date
November 27 2017
End Date
December 31 2020
Last Update
February 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Chinese PLA General Hospital
Beijing, China, 100853